



## **SAGE Extraordinary Meeting**




Update on recent developments including COVAX

May 27 2021

Dr. Kate O' Brien

Director, Department of Immunization, Vaccines and Biologicals

# 1,742M doses of COVID-19 vaccine have been administered<sup>1</sup> in 210 countries, areas, territories & economies<sup>2</sup>

 COVAX participants that received COVAX doses (incl. ones that started with others)  
 Economies vaccinating only with bilateral doses or donations  
 Economy not yet started vaccinating



**COVAX has shipped  
72.0M doses to 125  
participants<sup>4</sup>**

**1,742M vaccine doses<sup>1</sup>  
have been administered  
globally**


**Campaigns have not yet  
started in 10 countries,  
economies & territories<sup>2</sup>**

Note: The designations employed and the presentation of these materials do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

1. Source of data: Bloomberg; 2. Total of 220 countries, areas, territories & economies: 218 economies listed by World Bank + WHO Member states Cook Islands + Niue
3. WHO COVID-19 Dashboard at <https://covid19.who.int/>; 4. Including donations of doses through COVAX

# Of the 15 COVID-19 vaccines now in use, AstraZeneca & Pfizer products remain the most prevalent

■ SII - Covishield only ■ AstraZeneca - Vaxzevria only ■ Unspecified or both



## 32 economies are using 1 vaccine; 177 are using 2 or more vaccines


1. World Bank classification (2021) of 218 economies. Note: The term country, used interchangeably with economy, does not imply political independence but refers to any territory for which authorities report separate social or economic statistics.

# Inequity is decreasing, but HICs have administered 69x more doses per inhabitant than LICs

● HIC ■ UMIC ▲ LMIC ◆ LIC ● Worldwide

## COVID-19 doses administered per 100 population

Average per income group



Ratio of  
HIC to LIC

0 doses in LICs

10,000x

200x


84x

69x

## Mongolia and Bhutan are the only LMIC/LIC that have achieved theoretical coverage of >20%<sup>1</sup>

● HIC ■ UMIC ▲ LMIC ◆ LIC — Median

### Cumulative COVID-19 doses administered per 100 population




Income group	HIC	UMIC	LMIC	LIC
<b>Population, millions</b>	1,238	2,872	2,954	686
<b>Population in economies above 40 d/100, millions and %</b>	887 73.6%	8 0.3%	4 0.1%	0 0.0%
<b>Economies above 40 d/100, # and % of total</b>	51 61.4%	5 8.9%	2 4.0%	0 0.0%


1. As defined by 40 doses administered per 100 population (at least 20% theoretical coverage, assuming most vaccine types require two doses)

# While more than 20% of global deals, shipped COVAX doses represent only 4.9% of doses administered globally


COVAX deals vs global deals<sup>1</sup>



Ratio of COVAX doses delivered to total doses administered worldwide, expressed as %





# Overview of WHO EULs and SAGE recommendations



1. MFDS Korea EUL finalized Feb 15. EMA SK-Catalent followed Apr 16 and Wuxi (DS) Apr 30

# Misaligned supply expectations, low Vx rollout and low Vx confidence as particularly high risks to fast delivery

Supply/shipment risks 	
<b>A Misaligned supply expectations</b>	Very high
<b>B Highly fragmented supply and delivery</b>	High
<b>C Changes in product preferences</b>	High
<b>D Lack of 'shipment readiness'</b>	High

Programmatic/operational risks 	
<b>E Countries not ready to implement</b>	High
<b>F Low vaccine uptake/roll out</b>	Very high
<b>G Negative impact on health services</b>	High
<b>H Insufficient operational funding</b>	High
<b>I Multiple products in one country</b>	High
<b>J Reduced/low vaccine confidence</b>	Very high
<b>K High/negative wastage rate</b>	High
<b>L Target populations missed</b>	High
<b>M Serious adverse events not detected</b>	High